New Era in HCV Management: Primary Care Innovations

Marwan Haddad MD, MPH, AAHIVS
Medical Director of HIV, HCV, and Buprenorphine Services
Community Health Center, Inc., Connecticut
September 24, 2015
Continuing Medical Education Disclosure

- **Program Faculty:** Marwan Haddad MD, MPH, AAHIVS
- **Current Position:** Medical Director of HIV, HCV, and Buprenorphine Services
  Community Health Center, Inc., CT
- **Disclosure:** Speaker’s Bureaus: Gilead, BMS, Merck (Spouse Only). Presentation contains recommendations for HCV treatment regimens that are not FDA approved.

It is the policy of The National LGBT Health Education Center, Fenway Health that all CME planning committee/faculty/authors/editors/staff disclose relationships with commercial entities upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and, if identified, they are resolved prior to confirmation of participation. Only participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in this CME activity.
Learning Objectives

By the end of this webinar, learners will be able to

1. Summarize evidence-based recommendations for HCV screening.
2. Apply management recommendations for chronic HCV mono-infection and HIV-HCV co-infection in primary care.
Outline

- Epidemiology and Rationale
- Transmission
- Screening
- Management and Treatment
- Challenges of Integration in Primary Care
Epidemiology

- HCV is the most common chronic blood-borne infection.
- About 3.2 million people are chronically infected with HCV in the U.S.
- About half are not aware of their infection.
- Majority of HCV infections are among individuals born between 1945 and 1965.

HCV Incidence: CDC Estimates

Reported Number of Acute Hepatitis C Cases:
United States, 2000-2013

Source: National Notifiable Diseases Surveillance System (NNDSS)
Epidemiology

- 15,106 deaths (4.6 deaths per 100,000) estimated to be caused by HCV in 2007.
  - Increased to 4.8 deaths per 100,000 in 2011

CDC Website; Annals of Internal Medicine, 2012. 156 (4): p. 271-278
HCV Genotype Distribution

- 6 known genotypes.
- Little difference among them regarding transmission and natural history.
- Genotype 1 is most common in the United States.
Rationale for HCV Integration in 2015

- All oral regimens available for all HCV genotypes.
  - Some as simple as one pill once a day
- Pegylated interferon seldom needed.
- Highly effective; well tolerated; short treatment duration.
- Consideration of HCV management in primary care essential to ensure every HCV patient has the opportunity to access curative therapy.
HCV Transmission

- Injection Drug Use
  - Most common means in U.S.
  - ~33% of IDUs aged 18-30 infected
  - ~70-90% of older IDUs infected
HCV Transmission

- Sex with HCV-infected persons
  - Heterosexual Risk
    - Meta-analysis of several large prospective studies.
    - Heterosexual discordant stable couples with 10 or more years of follow up.
    - No increased risk of sexual transmission of HCV.
    - Even after ~ 750,000 vaginal and anal contacts
    - Probability of transmission less than 1 in 10 million sexual contacts

HCV Transmission

- Sex with HCV-infected persons
  - HIV-infected MSM
    - Studies limited, mainly in Europe; few in U.S., Australia.
    - Dutch study: increase from 0.08 cases/100 pys in ’84-’99 to 0.87 cases/100 pys in ‘00-’03.
    - UK study: incidence increased by 20% every year since ‘02.
    - French study: increase from 1.2/1000 pys before ‘03 to 8.3/1000 pys after ‘03.
    - Amsterdam study: HIV+ MSM 43 times more likely to get HCV infected than HIV- MSM.
  - Risk factors implicated but not consistent in studies:
    - condomless anal sex, fisting, group sex, multiple partners, other STIs, drug use, shared sex toys, HIV serosorting

### Risk Factors for HCV Acquisition in HIV+ MSM

- MOSAIC study, case-control, in Netherlands
- N= 82 HIV+ MSM with acute HCV infection with 131 controls (median age 46; in 2009+)

<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection Drug Use</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Ulcer-causing STIs (syphilis, genital herpes, LGV)</td>
<td>~ 5</td>
</tr>
<tr>
<td>Condomless receptive anal sex</td>
<td>~ 5</td>
</tr>
<tr>
<td>Sharing sex toys</td>
<td>~ 4</td>
</tr>
<tr>
<td>Sharing straws for drugs before or during sex</td>
<td>~ 3.5</td>
</tr>
<tr>
<td>Unprotected fisting</td>
<td>~ 3</td>
</tr>
<tr>
<td>Lower CD4 count at last visit before testing HCV+</td>
<td>~ 1.7 /cubic root lower</td>
</tr>
</tbody>
</table>

Risk Factors for HCV Acquisition in HIV+ MSM

- No association with having more sex partners, group sex, involvement at sex parties, anal rinsing or douching, or rectal bleeding in this analysis.

- Role of CD4 count unclear
  - Does a lower count facilitate acquisition or does acute infection cause a decrease in CD4 count or both?
  - Many HIV+ men with sexually transmitted HCV have high CD4 counts.

HCV Transmission

- Sex with HCV-infected persons
  - HIV-uninfected MSM
    - Variable study results and usually rare sexual transmission
    - Amsterdam study: 0 cases/100 p ys
    - UK study: 1.5 cases/1000 p ys
    - Studies in Canada, Argentina, Australia no association with sexual transmission
      - One Australian study showed an association but high rates of IDU confounding results
  - Omega Cohort Study
    - No increased risk, even with risky behavior e.g. multiple partners or unprotected anal sex
    - Pros: Large sample; controlled for all other risk factors
    - Cons: short observation time 1 year; few engaged in high risk behavior

Risk Factors for HCV Acquisition in HIV-MSM

- Retrospective study of acute HCV infection in HIV-MSM seen at sexual health clinics in London from 2010-2014.
- Only about 15% of 235,000 patients screened for HCV.
- 44 tested HCV positive
  - Rate of less than 1%
  - Median age 37; 67% white
  - 15 spontaneously cleared; 11 treated

Risk Factors for HCV Acquisition in HIV-MSM

- Risk factors identified:
  - Condomless anal sex, insertive and receptive
  - Group sex
  - Fisting
  - Intranasal drug use
  - Injection drug use
  - Sex while using drugs
  - Co-existing STIs

CDC’s 2015 STD Treatment Guidelines

- Since HCV transmission has not been demonstrated between heterosexual partners, condom use might not be necessary.
- Heterosexuals and MSM with HCV infection and more than one partner, especially those with HIV co-infection, should use male latex condoms to protect their partners against HCV and HIV.
HCV Transmission

- Birth to HCV infected mothers
  - Around 3-5% transmission; higher in HIV co-infected
- Needle stick injuries in healthcare settings
  - About 1.8% transmission but reported as high as 10%
- Receipt of donated blood, blood products, and organs
  - About less than 1 chance per 2 million units transfused
- Sharing personal items contaminated with infectious blood, such as razors or toothbrushes
  - Considered an inefficient means

www.cdc.gov
USPSTF Screening Recommendations

- US Preventive Services Task Force (USPSTF)* recommends:
  - Testing for HCV infection in patients at high-risk for infection. (B recommendation)
  - One-time testing in adults born between 1945 and 1965. (B recommendation)

*CDC, AASLD, IDSA, ACG have similar recommendations.
CDC Definition of High Risk

- Persons who have ever injected drugs, including only once
- Persons with HIV infection
- Persons with signs or symptoms of liver disease
  - e.g. persistently abnormal liver enzymes
- Persons with known exposures to HCV
  - e.g. HCWs after needle sticks, mucosal exposures to HCV-infected blood
- Children born to HCV-infected mothers
- Persons who were ever on chronic hemodialysis
- Recipients of blood transfusions and solid organ transplantations before July 1992
- Recipients of clotting factor concentrates before 1987
Other Risk Factors

- AASLD/IDSA/IAS-USA add as high risk:
  - Non-injecting illegal drug use
  - Tattooing
  - Incarceration
  - HIV infected MSM

- CDC lists as uncertain:
  - Non-injecting illegal drug use
  - Tattooing/body piercing
  - Multiple sex partners or STIs
  - Long term sex partners of HCV+ persons
  - Recipients of transplanted tissue (e.g. corneal, MSK, skin, ova, sperm)
**Natural History of HCV Infection**

**Exposure (Acute Phase)**
- 15-25% resolved
- 75-85% chronic

**Chronic**
- 20% cirrhosis

**Cirrhosis**
- 6%/yr ESLD
- 4%/yr HCC
- 3–4%/yr transplant/death

~20 year progression rate accelerated with HIV, HBV, alcohol

5-year survival in patients with HCC is < 5%²

HCC = hepatocellular carcinoma
ESLD = end-stage liver disease

Time (yr)
- 10
- 20
- 30

Hoofnagle J. *Hepatology*. 1997;26(suppl 1):15S-20S.
Progression of Hepatitis C Disease

- Related Factors
  - Heavy alcohol consumption
  - HIV infection
  - Hepatitis B infection
  - Immunosuppression
  - Male
  - Infection at > 40 years

- Factors Not Related
  - ALT
  - HCV RNA level
  - HCV Genotype
  - Mode of HCV transmission

NIH Consensus Development Conference Statement, 2002
Poynard et al. Lancet 1997, 349: 825-832
Shiffman et al J Infect Dis 2000, 182: 1595-1601

![Diagram showing progression stages: 23% Normal ALT, 6% No fibrosis, 6% Mild, 26% Portal fibrosis, 39% Bridging, 6% Cirrhosis]
Stages and Symptoms of HCV Infection

**Acute Infection:** majority asymptomatic but fatigue, abdominal pain, anorexia, or jaundice may occur

**Chronic Infection:** no symptoms or fatigue, depression, abd discomfort, nausea, anorexia, joint/muscle pain

**Advanced Chronic Infection:** cirrhosis, ascites, encephalopathy, portal hypertension, varices/GI bleeding, liver cancer

Sequence of HCV Screening and Confirmation

- HCV Ab +
- HCV RNA Quantitative
- Chronic Infection

- HCV Ab + (signal to cutoff titer)
- Cleared Infection

- HCV Ab -
- False Positive

- low titer
- high titer

- high titer
HCV Baseline Lab Investigations

- HCV RNA/Genotype
- CBC including platelets & diff
- Comprehensive Metabolic Panel including
  - Albumin
  - ALT/AST
  - Alkaline phosphatase
  - Creatinine
- PT/INR/PTT
- HIV
- Hepatitis A/B panel
  - HAV Ab total, HBV sAg, HBV sAb quantitative, HBV cAb total
- Liver Fibrosis Panel
Liver Imaging and Biopsy

- Abdominal U/S:
  - Assesses liver and spleen size and larger liver tumors (>3 cm)
  - Not good at assessing severity of liver disease
- CT scan or MRI of Abdomen
  - Better at assessment of liver tumors (<3 cm)
- Fibrosis Assessment
  - Liver biopsy
    - Invasive, expensive
  - Serum markers
    - E.g. FibroSure; Liver fibrosis panel
    - Blood test, cheap
  - Transient elastography
    - E.g. FibroScan
    - Noninvasive, availability issues
Current Available HCV Medications

- Pegylated Interferon
  - 180 mcg s/c injection
  - once a week
- Ribavirin (200mg, 400 mg, 600 mg)
  - Weight-based 1000 mg (<75 kg) or 1200 mg (>75 kg) daily in divided doses with food
Current Available HCV Medications

- Direct Acting Antivirals (DAAs)
  - Protease Inhibitors
    - First generation (not used anymore)
      - Telaprevir, Boceprevir
    - Second generation
      - Simeprevir (Olysio) 150 mg
      - one pill once a day with food
  - Polymerase Inhibitors
    - Sofosbuvir (Sovaldi) 400 mg
      - one pill once a day with/without food
  - NS5A Inhibitor
    - Daclatasvir (Daklinza) 60 mg
      - one pill once a day with/without food
Current Available HCV Medications

- Combination Direct Acting Antivirals (DAAs)
  - Harvoni
    - NS5A inhibitor/NS5B polymerase inhibitor
    - ledipasvir 90 mg /sofosbuvir 400mg
    - One tablet once a day
  - Viekira-Pak
    - NS3/4A protease inhibitor, NS5A inhibitor, NS5B polymerase inhibitor
    - paritaprevir 150 mg/ritonavir 100 mg/ombitasvir 25 mg once daily plus twice-daily dosed dasabuvir 250 mg
    - Three tablets in am and one tablet in pm
HCV Medication Cost
Is HCV Curable?

- Data from 9 randomized, multicenter trials
- 997 patients with a sustained virologic response (SVR24) defined as undetectable HCV RNA 24 wks post end of treatment.
  - 163 patients received pegylated interferon monotherapy
  - 741 patients received pegylated interferon and ribavirin
  - 93 HIV/HCV patients received pegylated interferon and ribavirin
- Overall, 99% of patients maintained undetectable HCV RNA at a mean of 4.1 years (0.4-7 years).
- 8 patients (0.8%) became HCV RNA positive a mean 2 years after finishing therapy. Unclear if this was due to relapse or re-infection.

Swain M et al. Presented at EASL 2007, April 11-15, Barcelona, Spain, Abstract 1
Is HCV Curable?

- SVR24 vs. SVR12
  - FDA has more recently determined SVR12 to be as valid as SVR24 as an efficacy endpoint based on high correlation.
  - Recent study finds >99% concordance between SVR12 and SVR24 with SOF-based regimens.
- With the advent of the Direct Acting Antiviral (DAA) medications, SVR12 rates have reached 80-100% in clinical trials, varying based on genotype, fibrosis stage, and prior treatment experience.

Treatment

- Treatment recommendations changing quickly.
- [http://hcvguidelines.org/](http://hcvguidelines.org/)
  - AASLD/IDSA/IAS-USA living document
## Initial Treatment Recommendations

<table>
<thead>
<tr>
<th>Genotype 1</th>
<th>Genotype 2</th>
<th>Genotype 3</th>
<th>Genotype 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOF/LDV x 12 wk*</td>
<td>DCL+SOF x 12 wk</td>
<td>DCL+SOF x 12 wk +/-RBV x 24 wk if cirrhosis</td>
<td>SOF/LDV x 12 wk</td>
</tr>
<tr>
<td>DCL+SOF x 12 wk +/- RBV x 24 wks if cirrhosis</td>
<td>SOF+RBV x 12 wk</td>
<td>SOF+P/R x 12 wk</td>
<td>PTV/RTV/OBV+DSV +RBV x 12 wks</td>
</tr>
<tr>
<td>PTV/RTV/OBV+DSV+RBV x 12 wks</td>
<td>X 16 wks if cirrhosis</td>
<td>SOF+RBV x 24 wk</td>
<td>SOF+P/R x 12 wk</td>
</tr>
<tr>
<td>1a: 24 wks if cirrhosis 1b: RBV if cirrhosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+SMV +/- RBV x 12 wk X 24 wks if cirrhosis</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* x 8 wk if RNA < 6 million, Rx-naive, no cirrhosis, HIV uninfected

PTV = paritaprevir; RTV = ritonavir; OBV = ombitasvir; DSV = dasabuvir; RBV = ribavirin; SOF = sofosbuvir; LDV = ledipasvir; DCL = daclatasvir
**HCV/HIV Co-infection**

- Treatment and retreatment same as mono-infected.
- Main issue: drug interactions with ARVs.
- ARV regimen changes should be handled in collaboration with HIV practitioner.
  - Some examples:
    - DCL dose adjustment may be needed.
      - 30 mg with ATV/r and 90 mg with EFV and ETV.
    - LDV increases TFV levels
      - avoid if CrCL<60
      - avoid with PI/r
    - PTV/RTV/OBV+DSV can be used with ATV, DTG, FTC, 3TC, RTG, TFV.;
      - RTV dose may need to be adjusted.
      - Not use with DRV, EFV, LPV/r, RPV.
    - SOF/LDV not to be used with EVG/COBI/TDF/FTC.
HCV Drug Interactions

- http://www.hep-druginteractions.org/
Who Should Be Treated?

- Treatment is recommended for ALL patients except those with short life expectancy
- Prioritizing immediate treatment may be necessary
  - Advanced fibrosis/Cirrhosis
  - Liver transplant
  - Severe extrahepatic symptoms
- Other considerations:
  - Available resources
    - E.g. insurance coverage
  - Drug/alcohol use
  - Adherence
    - E.g. housing stability
  - Treatment should not be withheld simply on the basis of active substance use or cost.
Role of Primary Care

- HCV screening
  - Risk-based and one-time birth cohort screening with HCV Ab.
- Confirmation of HCV infection
  - HCV RNA testing required to confirm infection.
- Counseling
  - HCV transmission/prevention
  - Risks of alcohol use
- Screening in HCV-infected individuals
  - HIV/HAV/HBV
  - Alcohol and substance use disorders
Role of Primary Care

- Vaccination
  - Hep A and B

- Baseline liver assessment
  - CBC, INR, albumin, AST/ALT, bilirubin, alkaline phosphatase, GFR

- Treatment and Referral
  - Patients need to be informed of current effective, well tolerated treatments and referred to provider with HCV treatment expertise.
Key Challenges with Integration in Primary Care

- HCV expertise
  - E.g. Project ECHO model of care delivery
- Potential costs /burden to health center
  - HCV medications
    - Coverage restrictions
    - Prior authorizations
    - Patient assistance programs
  - Lab tests, imaging, biopsies
    - Uninsured
    - Imaging/biopsies may not be needed
- Medical visits
  - On average, about 3 visits during 12 week treatment
Key Challenges with Integration in Primary Care

- Liver fibrosis assessment
  - Interventional radiology
  - Non-invasive alternatives
    - serum markers, transient elastography

- Medication-related issues
  - Adherence
  - Drug-drug interactions
  - Side effects

- Ongoing alcohol and drug use

- Cirrhosis
  - Hepatocellular carcinoma screening
  - Referral to GI/transplant team
Summary

- HCV integration into primary care is essential to be able to manage the HCV epidemic in the U.S.
- Primary care centers can play an integral role in HCV management and treatment.
- Most management recommendations fall within the purview of primary care and can be easily adopted by health centers.
  - Screening (birth cohort and risk-based)
  - Prevention and transmission counseling
  - Lab tests
  - Vaccination
  - Drug and alcohol counseling
- Treatment of HCV has now become easier and can be managed in primary care with expert guidance, e.g. Project ECHO models of care delivery
Thank you!

Marwan Haddad MD, MPH, AAHIVS
haddadm@chc1.com